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DNA repairAlzheimer's disease (AD) is an age-related progressive neurodegenerative disease affecting thousands of
people in the world and effective treatment is still not available. Over two decades of intense research using
AD postmortem brains, transgenic mouse and cell models of amyloid precursor protein and tau revealed that
amyloid beta (Aβ) and hyperphosphorylated tau are synergistically involved in triggering disease
progression. Accumulating evidence also revealed that aging and amyloid beta-induced oxidative DNA
damage and mitochondrial dysfunction initiate and contributes to the development and progression of the
disease. The purpose of this article is to summarize the latest progress in aging and AD, with a special
emphasis on the mitochondria, oxidative DNA damage including methods of its measurement. It also
discusses the therapeutic approaches against oxidative DNA damage and treatment strategies in AD., Division of Neuroscience, Oregon National Primate Res
625; fax: +1 503 418 2701.
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Alzheimer's disease (AD) is the most common progressive
neurodegenerative disorder and the major cause for dementia [1].
As people age, memory and the ability to carry out tasks often decline
and their risk for neuronal damage increases. AD is strongly an age-
associated disease. An estimated 5.4 million Americans have AD;
approximately 200,000 people aged b65 years with AD comprise the
younger-onset AD population, and over 50% of individuals that are
85 years old will be affected by AD [2]. Pathologically, AD is associated
with extracellular amyloid-beta (Aβ) deposits and intracellular
aggregates of hyperphosphorylated tau, and neuroﬁbrillary tangles,
and also accompanied by oxidative stress/mitochondrial dysfunction
and synaptic damage [1,3–7] (Fig. 1). Aging is considered as a major
risk factor in AD. However, the mechanisms that underlie aging
process in AD progression are not fully understood.
Several hypotheses have been proposed to explain the causes of
aging.Mechanisms that govern genome integrity and stability aremajor
guarantors of viability and longevity. 1) Telomere-shortening and its
relationship with aging is extensively investigated and reported that
changes in telomere structure and function are linked to aging [8–10]. 2)
Activation of p53 is emerged as prime factor of a functional decline of a
tissue in aging [11]. 3) Signaling that control energy production and
metabolism, including insulin/IGF pathway is another important
mechanism that contributes to aging [12,13]. 4) The mitochondrial
oxidative damage is the strong cellular event involved in aging process
[6,14–16]. 5) The latest evidence suggests a unifying mechanism that
involves a combination of factors in aging, including telomere
shortening, and mitochondrial oxidative damage, p53 activation, and
reducedperoxisomeproliferator-activated receptor gamma, coactivator
1 alpha and beta (PGC-1α and PGC-1β) [17,18].
Among these, mitochondrial oxidative damage has been found
excessively in the brains of aged people, especially AD patients and
also AD-like transgenic animal models. The purpose of this article is to
summarize the recent progress of aging and Aβ-induced oxidative
DNA damage and related pathways in the pathogenesis of AD. Further,Fig. 1. Factors that are responsible for causing Alzheimer's disease (AD). Genetic
mutations in amyloid precursor protein, presenilin 1 and presenilin 2 cause early-onset
familial AD. Genetic variants in sortilin related receptor 1, clusterin, complement
component receptor 1, CD2AP, CD33, EPHA1, and MS4A4/MS4A6E genes contribute to
late-onset AD, in addition to ApoE 4/4 genotype. Aging, lifestyle activities and oxidative
DNA damage are major contributing factors for the development of AD.this article also discusses therapeutic approaches of oxidative DNA
damage in treating patients with AD.
2. Cellular changes of aging and oxidative DNA damage
Aging is a complex process that has been linked to accumulation of
DNA damage. In mammals, including humans, an accumulation of
oxidative DNA damage in different tissues including brain is observed
during aging [19–21]. Recent observation from young, middle and old
age mice groups further indicate that oxidative DNA damage is
increased with aging (Mao and Reddy, unpublished observations).
Telomeres, the ends of linear chromosomes, repetitive DNA regions of
hexanucleotide repeats, protect chromosomal ends from deteriora-
tion during DNA replication. Telomerase (TERT), a reverse transcrip-
tase, forms a complex with an RNA template and cofactors to extend
telomeres. The shelterin protein complex then binds the 3′ single-
stranded end of telomeric DNA, protecting it from DNA damage
responses [22,23]. Interestingly, TERT is also localized inmitochondria
and regulates/modulates oxidative damage on the mtDNA [24].
Inhibition of TERT function and related process leads to short
telomeres and premature age-related diseases. In fact, telomere
shortening represents a cell-intrinsic mechanism leading to DNA
damage accumulation and activation of DNA damage at checkpoints
in aged cells. Activation of DNA damage checkpoints in response to
telomere malfunction results in induction of cellular senescence — a
permanent cell cycle arrest. Senescence represents a tumor suppres-
sor mechanism protecting cells from evolution of genomic instability
and transformation [25]. As a drawback, telomere shorteningmay also
limit tissue renewal and regenerative capacity of tissues in response
to aging and chronic disease.
Short telomeres are a hallmark of dyskeratosis congenita, which is
caused by mutations in genes (including TERT) controlling telomere
homeostasis. Induced pluripotent stem cells from dyskeratosis
congenita patients demonstrate that telomere shortening, induced
by mutations of TERT and other related genes, eventually results in
loss of self-renewal [26]. In aged organs, telomere shorteningmay also
increase the risk of age-related diseases, including neurodegenerative
diseases and cancer, by initiation of chromosomal instability, loss of
proliferative competition of aging stem cells, and selection of aberrant
growing clones. Consequently, aged individuals are more susceptible
and vulnerable to various diseases. Recently, proteins were found in
human serum, which are induced by telomere dysfunction and DNA
damage. It was shown that these proteins (CRAMP, EF-1alpha,
stathmin, n-acetyl-glucosaminidase and chitinase) increase in aged
people and are further elevated in geriatric patients, representing new
biomarkers of human aging and disease [21,27].
Interestingly, lifestyle factors (such as exercise, smoking, body
mass) also affect on the expression of these serum markers of DNA
damage. The expression of biomarkers of DNA damage correlated
positively with other cellular aging marker p16 (INK4a) expression
and negatively with telomere length in peripheral blood T-lympho-
cytes. Together, these data provide experimental evidence that both
aging and lifestyle impact on the accumulation of DNA damage during
human's aging [28].
Emerging evidence suggests that telomere shortening can limit the
function and maintenance of adult stem cells, which are of utmost
importance for organ maintenance and regeneration. In mouse
models, telomere dysfunction leads to a depletion of adult stem cell
compartments suggesting that stem cells are very sensitive to DNA
damage [29].
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neuronal differentiation, as adultmultipotent progenitorswith critically
short telomeres yield reduced numbers of neurons that, furthermore,
exhibit underdeveloped neuritic arbors. Genetic data indicate that the
tumor suppressor protein p53 not only mediates the adverse effects of
telomere attrition on proliferation and self-renewal but it is also
involved in preventing normal neuronal differentiation of adult
progenitors with dysfunctional telomeres. The effect of p53 on
neuritogenesis is mechanistically linked to its cooperation with the
Notchpathway in the upregulation of small GTPase RhoAkinases, Rock1
and Rock2, suggesting a potential link between DNA damage and the
Notch signaling pathway in the control of neuritogenesis [30]. It has also
been shown that telomerase expression is downregulated in the
subependymal zoneof agingmice leading to telomere length reductions
in neurosphere-forming cells and deﬁcient neurogenesis and neurito-
genesis, it suggests that age-related deﬁcits could be caused partly
by dysfunctional telomeres and demonstrates that p53 is a central
modulator of adult neurogenesis, regulating both the production and
differentiation of postnatally generated olfactory neurons [30].
In addition, the transcription factor p53 protects neurons from
transformation and DNA damage through the induction of cell-cycle
arrest, DNA repair and apoptosis in a range of in vitro and in vivo
conditions. Indeed, p53 has a crucial role in eliciting neuronal cell
death during development and in adult organisms after exposure to a
range of stressors and/or DNA damage [31].
p53 takes a critical part in a number of positive and negative
feedback loops to regulate aging, carcinogenesis and other biological
processes. Uncapped or dysfunctional telomeres are an endogenous
DNA damage that activates ATM kinase and then p53 to induce cellular
senescence or apoptosis. Recent studies have shown that p53, a
downstream effector of the telomere damage signaling, also functions
upstream of the telomere‐capping protein complex by inhibiting one of
its components, TRF2 (telomeric repeat binding factor 2). Since TRF2
inhibition leads to ATM activation, a novel positive feedback loop exists
to amplify uncapped telomere‐induced, p53‐mediated cellular re-
sponses. Siah1 (seven in absentia homolog 1), a p53‐inducible E3
ubiquitin ligase, plays a key role in this feedback regulation by targeting
TRF2 for ubiquitination and proteasomal degradation [32].
In addition to telomere shortening mechanism, ROS and mito-
chondrial dysfunction as further described below, and environmental
factors (e.g. toxic chemicals and irradiation), as well as DNA repair
defects also contribute to accumulating DNA damage during aging
[21,33,34] (Fig. 1). Interestingly, recent ﬁndings suggest environmen-
tal genotoxins, speciﬁcally methylazoxymethanol (MAM), the geno-
toxic metabolite of the cycad azoxyglucoside cycasin, target common
pathways involved in neurodegeneration and cancer, the outcome
depending on whether the cell can divide (cancer) or not (neurode-
generation). Exposure to MAM-related environmental genotoxins
may have relevance to the etiology of related tauopathies, notably, AD
[35]. It also has been indicated that DNA damage is an initial and
critical contributor for aging, and various factors that affect aging may
all function ultimately through the accumulation of persistent DNA
lesions containing unrepairable DNA double-strand breaks [20,36].
Mice deﬁcient in the Polycomb transcriptional repressor Bmi1
develop numerous abnormalities including a severe defect in stem cell
self-renewal, severe neurological abnormalities, alterations in thy-
mocyte maturation and a shortened lifespan [37,38]. Cells derived
from Bmi1−/− mice have impaired mitochondrial function, a marked
increase in the intracellular levels of ROS and DNA damage, as well as
subsequent engagement of the DNA damage response pathway. More
interestingly, the antioxidant N-acetylcysteine or genetic disruption
of the DNA damage response pathway by Checkpoint kinase (Chk) 2
deletion can rescue many deﬁcits, and eventually elongates signiﬁ-
cantly lifespan [38]. These observations further indicate the important
role of mitochondria, ROS and DNA damage in aging and neurode-
generative diseases.Therefore oxidative DNA damage may be the center of aging and
age-related diseases such as AD. Hence, protection from DNA damage
presents a basic approach for elongation of healthy age and treatment
of such age-related diseases.
3. Amyloid beta, particularly Aβ42 in Alzheimer's disease
Amyloid-beta peptide (Aβ) appears to play a pivotal role in the
development of AD and amyloid plaques as the most important
hallmark is routinely used for diagnosing AD in brain tissue [5,39,40].
Increasing studies demonstrated the toxicity of diverse Aβ species in
vitro and in vivo, conﬁrming the importance of age-dependent Aβ
accumulation in AD pathogenesis [41–44]. A recent study revealed
that area-speciﬁc vulnerability to Aβ deposition is associated with
local levels of brain metabolism and neuronal activity, indicating that
Aβ and glucose metabolism are linked to AD [45]. Transgenic mice (at
least APP23 line), overexpressing mutant human amyloid precursor
protein (APP), exhibit selective neuronal death in the brain regions
such as hippocampus and cortex that are most affected in AD,
suggesting that amyloid plaque formation is directly involved in AD
neuron loss [46]. In APP/PS1 transgenic mice, global neocortical
neuron loss is not apparent up to 8 months of age, but local neuron
loss in the dentate gyrus is observed [47]. Recent stereological analysis
of neocortical neuron number in subregions with high neuron density
such as the granule cell layer of the dentate gyrus, modest but
signiﬁcant neuron loss is also found [48]. In addition, parallel studies
using multiphoton microscopy and in vivomicrodialysis revealed that
pharmacological reduction of soluble extracellular Aβ by as little as
20–25% was associated with a dramatic decrease in plaque formation
and growth. Interestingly this small reduction in Aβ synthesis was
sufﬁcient to reduce amyloid plaque load in 6-month-old but not 10-
month-old mice [49]. These observations demonstrate that amyloid
plaque effects ﬁrst on some critical regions and vulnerable neurons in
brain, and early interference that reduces the Aβ level and the plaques
prior to neurons die is the key for treatment of this disease.
Furthermore, microinjection of plaque-equivalent concentrations of
ﬁbrillar Aβ in the aged rhesus monkey cerebral cortex results in
profound neuronal loss, tau phosphorylation and microglial prolifera-
tion [50], indicating the both direct and indirect toxic roles to neuron of
Aβ plaques. Recent evidence further indicates that the ﬁbrillar
conformation of Aβ deposited in compact plaques is associated with
the pathologies observed in AD. Quantitative analysis revealed that the
area adjacent to ﬁbrillar Aβ, containing compact but not diffuse plaques
in aged rhesus, aged human, and AD cortex, displays signiﬁcant loss of
neurons and small but statistically signiﬁcant reduction in the density of
cholinergic axons [51].
The Aβ peptide is a 38–43 amino acid in length and is generated by
proteolytic processing of the APP, a cell-surface receptor via β-secretase
(β-amyloid cleavage enzyme, BACE1)andγ-secretase complex contain-
ing presenilins consequently [1,40,52–54]. Although several small Aβ
molecules exist in the AD brain, themost common species are Aβ40 and
Aβ42. Aβ40 is the major species in soluble Aβ, and is constitutively
secreted into culturemediumand cerebrospinalﬂuids [55,56]. However
a number of studies have shown that Aβ42 is in fact the predominant
species in the parenchymal amyloid deposits in AD brain, and it is an
initially deposited species; furthermore, elevated Aβ42 levels, aswell as
particularly the elevation of the ratio of Aβ42 to the shorter major form
Aβ40, has been identiﬁed as a key feature in early events in the
pathogenesis of AD [57]. The speciﬁc pathological importance of Aβ42
has drawn attention to seeking drugs that will selectively lower the
levels of this peptide through reducedproductionor increased clearance
while allowing normal protein processing to remain substantially intact
[52,57–60]. Furthermoremutations in APP and presenilin (PS1 and PS2)
genes have been shown to increase theproductionof the longerAβ form
Aβ42 relative to Aβ40, and to cause the familial autosomal dominant
form of AD [56,61–63]. Notably it has been shown that expression levels
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oxidative stress, ischemia and hypoxia [64,65].
Interestingly transgenic mice expressing high levels of Aβ40 do
not develop overt amyloid pathology. However, mice expressing
lower levels of Aβ42 accumulate insoluble Aβ1–42 and develop
compact amyloid plaques, congophilic amyloid angiopathy, and
diffuse Aβ deposits. Further, when mice expressing Aβ42 are crossed
with mutant APP (Tg2576) mice, there is also a massive increase in
amyloid deposition. These data further establish that Aβ42 is essential
for amyloid deposition in the parenchyma and also in vessels [66].
Plasma Aβ levels are elevated in early-onset AD caused by
autosomal dominant mutations. Recent ﬁndings showed that similar
genetic elevations exist in late-onset AD (LOAD), providing strong
evidence for the existence of novel, as yet unknown genetic factors
that affect LOAD by increasing Aβ [67]. Further, higher plasma Aβ42 at
baseline was a signiﬁcant predictor for the development of probable
or possible AD at 5 years [68]. Notably, in recent report of early AD
(predementia) trial design, it has been proposed that CSF Aβ42 or
amyloid PET imaging may be optimal biomarkers for selecting
subjects for anti-amyloid interventions [69].
Based on these fundamental observations, immunization of AD
patients with synthetic full length Aβ42 (AN1792, Elan Pharmaceu-
ticals) has been studied in a randomized, double-blind, placebo-
controlled phase 2a clinical trial [70,71]. Treatment was discontinued
following reports of encephalitis, and in the 1 year analysis of the
AN1792 data, vaccinated subjects did not show improvement and no
single test revealed beneﬁts of vaccination, although the Z-test was
consistent with a potential slowing of decline. However, approxi-
mately 4.6 years after immunization with AN1792, patients deﬁned as
responders in the phase 2a study maintained low but detectable,
sustained anti-AN1792 antibody titers and demonstrated signiﬁcantly
reduced functional decline compared with placebo-treated patients
[70]. These data support that Aβ immunotherapy, even though some
patients suffered side effects, may have long-term functional beneﬁts,
and further support the Aβ cascade hypothesis of AD. In addition,
another anti-amyloid therapy that reduces amyloid accumulation as
measured by PIB-PET in a recent clinical trial also supports the Aβ
hypothesis as well as the rationale for treatment with an anti-amyloid
intervention [72].
Overall, increasing evidence from human and animal models
demonstrates that amyloid plaque, especially derived from toxic
Aβ42, is the main hallmark of the AD, it is also a predictive marker for
the progression of preclinical to symptomatic AD, therefore treatments
especially early treatments that reduce Aβ production or increase its
clearance will have great promise as a potential therapeutic agent.
4. Hyperphosphorylated tau in Alzheimer's disease
The other hallmark of AD is intracellular neuroﬁbrillary tangles,
aggregated from hyper-phosphorylation of tau. Tau is a neuron-
speciﬁc microtubule-associated protein and a critical component of
the neuronal cytoskeleton. As one of the main microtubule-associated
proteins, tau will lose the ability to bind microtubules when the
homeostasis of phosphorylation and dephosphorylation is disturbed
in neurons. Then hyperphosphorylated tau eventually induces
neurodegeneration and neuron loss by disrupting neuronal cytoskel-
eton. It has been shown that DNA damage-activated kinases such as
Chk1 and Chk2may be involved in tau phosphorylation and toxicity in
the pathogenesis of AD [73]. Tau may also be a crucial partner of Aβ,
enhance the pathology of Aβ, as well as Tau-Aβ interplay a role in AD.
Research on the pathological changes in AD indicates that accumu-
lated Aβ in vivo may initiate the hyperphosphorylation of tau. Also,
the signal transduction pathways of tau hyperphosphorylation may
be related to accumulated Aβ [74–77]. Fibrillar Aβ containing compact
but not diffuse plaques in the aged rhesus cortex also contained
activated microglia and clusters of phosphorylated tau-positiveswollen neuritis [51]. On the other hand, recent study showed that
peptides from structure-based designs can disrupt the Aβ ﬁbril
formation of original proteins, including those, such as tau protein,
that lack fully ordered native structures. The speciﬁcally inhibiting
peptides have been designed on structures of dual-β-sheet ‘steric
zippers’, the successful inhibition of amyloid ﬁbril formation not only
shed light on new strategy of the development of therapeutics but
also strengthens the hypothesis that amyloid spines contain steric
zippers [78].
Tau, also known as axonal protein, has a dendritic function in
postsynaptic targeting of the Src kinase Fyn, a substrate of which is the
NMDA receptor (NR). Missorting of tau in transgenic mice expressing
truncated tau (Delta-tau) and absence of tau in tau (−/−) mice both
disrupt postsynaptic targeting of Fyn. This uncouples NR-mediated
excitotoxicity and hence mitigates Aβ toxicity. Delta-tau expression
and tau deﬁciency prevent memory deﬁcits and improve survival in
Aβ-forming APP23 mice, a model of AD. These deﬁcits are also fully
rescued with a peptide that uncouples the Fyn-mediated interaction
of NR and PSD-95 in vivo. These ﬁndings suggest that this dendritic
role of tau confers Aβ toxicity at the postsynapse with direct
implications for pathogenesis and treatment of AD [77].
Furthermore, recent studies in several APP and tau transgenicmouse
models revealed thatmitochondrial dysfunctionmight beapossible link
between Aβ and tau in AD pathology in vivo [79]. In a triple AD mouse
model, a massive deregulation of 24 proteins, of which one-third were
mitochondrial proteins mainly related to complexes I and IV of the
oxidative phosphorylation (OXPHOS).Notably, deregulation of complex
I was tau dependent, whereas deregulation of complex IV was Aβ
dependent. Synergistic effects of Aβ and tau were evident in 8-month-
old AD mice as only they showed a reduction of the mitochondrial
membrane potential at this early age. At the age of 12 months, the
strongest defects on OXPHOS, synthesis of ATP, and reactive oxygen
species (ROS) were exhibited in the AD mice, again emphasizing
synergistic, age-associated effects of Aβ and tau in perishingmitochon-
dria [79].
Overall, these observations indicate the involvement of tau and Aβ
synergistically, as well as the fundamental role of mitochondria in the
AD pathology.
5. Mitochondria in Alzheimer's disease
5.1. Mitochondria are the main source of ROS
Mitochondria are the cytoplasmic organelles essential for life and
death. Mitochondria perform several cellular functions, including
production of major part of cellular ATP, regulation of intracellular
calcium, the release of proteins that activate the caspase family of
proteases and free radical production and scavenging. The mitochon-
dria contain the respiratory chain or electron transport chain (ETC)
that is located in the inner mitochondrial membrane and consists of
ﬁve complexes (complexes I–V); the ﬁfth complex is directly involved
in ATP synthesis. The complexes of the mitochondrial respiratory
chain are made up of multiple subunits, and all contain proteins
encoded by nuclear DNA and mtDNA, except for complex II, which is
entirely encoded by nuclear DNA [16,80–82]. The mitochondria, also
called the powerhouses, are the chief energy-producing organelles in
the most cells, which providemost energy for our normal life. Usually,
energy in the form of ATP is efﬁciently produced via OXPHOS in the
mitochondrial respiratory chain. Several decades of research have
ﬁrmly established that ROS production is inherent to mitochondrial
oxidative metabolism, and mitochondria are believed to be the major
intracellular source of ROS. Several years of research revealed that free
radicals are produced at multiple sites in the mitochondria:
Complexes I and III produce superoxide radicals via electron leaks,
these radicals are dismutated by manganese superoxide dismutase,
generating H2O2 and oxygen. H2O2 is converted into H2O by either
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conditionally [82]. Components of tricarboxylic acid, including α-
ketodehydrogenase and pyruvate dehydrogenase generate superox-
ide radicals in the matrix. In addition, mitochondrial outer membrane
also produces free radicals via monoamine oxidase (localized on the
outer mitochondrial membrane), by catalyzing the oxidative deam-
ination of primary aromatic amines. This deamination is a quantita-
tively large source of H2O2.
A little ROS may not be toxic to cells, and may have some beneﬁt
roles to cells and homoeostasis. Recent data strongly suggest that ROS,
and speciﬁcally mitochondria generated ROS, are involved in physio-
logical signaling cascades regulating various cellular and organ
functions [84,85]. However, excessive and/or sustained increase in
ROS, may lead to oxidative stress, as aggravating or primary factors in
numerous pathologies, including aging andneurodegenerativediseases,
are widely recognized [6,82,85–87].
Mounting evidence suggests that Aβ cascade hypothesis remains
the major cellular event in AD; increasing evidence also indicates a
mitochondrial cascadehypothesis,which is formanyof thebiochemical,
genetic, pathological as well as clinic features of AD, and mitochondrial
dysfunction may initiate the disease, particularly sporadic AD [88]. This
hypothesis, importantly, is supported by recent observations showing
that early impairments of mitochondrial dysfunction and oxidative
stress may precede Aβ overproduction and deposition [88–92].
5.2. Mitochondrial localization of Aβ
As described above Aβ deposit is themain hallmark of AD, and Aβ42
is the most toxic peptide and the predominant species in the
parenchymal amyloid deposits inADbrain, and it is an initially deposited
species [57–60]. Although the classical view is that Aβ is deposited
extracellularly, both cellular and biochemical studies carried out in
different models of AD and aging have provided evidence that this
peptide can also accumulate inside neurons, target mitochondria, and
contribute to disease progression [93–99]. By using in vivo and in vitro
approaches, HanssonPeterson et al. demonstrated that Aβ is transported
into rat mitochondria via the translocase of the outer membrane (TOM)
and localizes within the mitochondrial cristae. A similar distribution
pattern of Aβ in mitochondria has been shown by immunoelectron
microscopy in human cortical brain biopsies [100].
It has been shown that Aβ42 can induce mitochondrial mislocaliza-
tion, which contributes to Aβ42-induced neuronal dysfunction in a
transgenic Drosophila model. In the Aβ42 ﬂy brain, mitochondria were
reduced in axons and dendrites, and accumulated in the somatawithout
severe mitochondrial damage or neurodegeneration. In contrast,
organization of microtubule or global axonal transport was not
signiﬁcantly altered at this stage. Aβ42-induced behavioral defects
were exacerbated by genetic reductions inmitochondrial transport, and
weremodulated by cAMP levels and PKA activity. Levels of putative PKA
substrate phosphoproteins were reduced in the Aβ42 ﬂy brains.
Importantly, perturbations in mitochondrial transport in neurons
were sufﬁcient to disrupt PKA signaling and induce late-onset
behavioral deﬁcits, suggesting a mechanism whereby mitochondrial
mislocalization contributes to Aβ42-induced neuronal dysfunction.
These results demonstrate that mislocalization of mitochondria un-
derlies the pathogenic effects of Aβ42 in vivo [101].
5.3. Aβ induces ROS production
Oxidative stress and its sequelae are likely related to both
apoptotic and necrotic mechanisms of neurotoxicity. There is
evidence suggesting that tissues from both AD patients and in-
dividuals with mild cognitive impairment have elevated levels of
oxidative DNA damage [33]. And post-mortem tissue provides strong
evidence for signiﬁcant increased levels of cellular oxidative stress in
vulnerable regions (cortex and hippocampus) of AD brains comparedto aged controls [3,33,102,103]. Importantly, Aβ peptides directly
initiate free radical/ROS formation, cellular dysfunction, and subse-
quent neuronal death [104–107]. Furthermitochondria are thought to
be the central target for oxidative stress induced damage [93,108].
Recent primary culture study has shown that oligomeric Aβ42 could
induce reactive ROS production from cortical neurons through
activation of NADPH oxidase [109]. Notably there is a defect in the
antioxidant defense system, which may lead to oxidative damage in
patients with AD. It has been found that erythrocyte antioxidant
enzyme activities (catalase, glutathione peroxidase GPX and super-
oxide dismutase SOD) were signiﬁcantly lower in patients with AD
compared with controls. These results suggest that alterations in
these enzymes may play a role in the etiopathogenesis of AD [110].
Therefore Aβ-associated oxidative stress and related antioxidant
defense systemmay be of fundamental importance in AD etiology and
pathogenesis.
5.4. Mitochondrial DNA changes in AD
The Aβ cascade hypothesis remains the main pathogenic model, as
suggested by familiar AD, mainly associated to mutation in APP and
presenilin genes. The remaining more than 98% of AD patients are
mostly sporadic late-onset cases, with a complex etiology due to
interactions between environmental conditions and genetic features
of the individuals. Somatic mutations in mitochondrial DNA (mtDNA)
could cause energy failure, increased oxidative stress and accumula-
tion of Aβ, which in a vicious cycle reinforces mtDNA damage and
oxidative stress. However, no clear causative mutations in the mtDNA
have been linked to AD, even some variations have functional
consequences, including changes in enzymatic activity [111]. Indeed,
results of studies on the role of mtDNA polymorphisms or
haplogroups in AD are controversial [91,112].
Recently, to investigate the possible association between mtDNA-
inherited sequence variation, a high resolution analysis (sequencing of
displacement loop and restriction analysis of speciﬁc markers in the
coding region of mtDNA) in 936 AD patients and 776 cognitively
assessed normal controls from central and northern Italy was
performed. Among over 40 mtDNA sub-haplogroups analyzed, sub-
haplogroup H5 is a risk factor for AD in particular for females and
independently from theAPOE genotype.Multivariate logistic regression
revealed an interaction betweenH5 and age.When thewhole sample is
considered, the H5a subgroup of molecules, harboring the 4336
transition in the tRNAGln gene, already associated to AD in early
studies, was about threefold more represented in AD patients than in
controls (2.0% vs0.8%; p=0.031), and itmight account for the increased
frequency of H5 in AD patients (4.2% vs 2.3%). The complete re-
sequencing of the 56mtDNAs belonging toH5 revealed that ADpatients
showed a trend towards a higher number of somatic mutations in tRNA
and rRNA genes when compared with controls [113].
The ultrastructural features of vascular lesions and mitochondria
in brain vascular wall cells from human AD, and APP transgenic
positive (Tg+) mice have been studied. In situ hybridization using
mtDNA probes for human wild and 5 kb deleted types and mouse
types that was performed along with immunocytochemistry have
shown that there was a higher degree of mitochondria DNA deletion
along with amyloid deposition, overexpression of oxidative stress
markers, and mitochondrial structural abnormality in the vascular
walls of the human AD, Tg (+) mice compared to age-matched
controls. Therefore, selective pharmacological intervention, directed
for abolishing the chronic hypoperfusion state, would possibly change
the natural course of development of dementia [114].
5.5. Mitochondrial dysfunction in AD
It has been shown that impairment occurs to all ﬁve of the
mitochondrial OXPHOS complexes in the AD brain. Mitochondrial
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reduced ATP synthesis, occurs early in AD. Additionally, mitochondrial
dysfunction is proposed to link amyloid deposition and neuronal
synaptic loss. Thus, the existence of mitochondrial dysfunction is
important in AD [96,115].
Age-dependent accumulation of mutations in mtDNA and result-
ing increase in oxidative stress and impairment in mitochondrial
respiratory chain, especially complex IV, gained attention as potential
factors that could participate in the onset of sporadic AD [16,88]. In
fact, a reduced activity of the cytochrome c oxidase (COX, complex IV
of respiratory chain) has been reported in different brain regions of
AD patients [116].
COX activity was also decreased in AD transgenic (Tg2576) mice,
suggesting that mutant APP/Aβ impair mitochondrial metabolism in
AD. Furthermore, an increase in hydrogen peroxide and a decrease in
COX activity were found in young Tg2576 mice, prior to the
appearance of Aβ plaques [93]. Also, in vitro study using primary
neuron culture and confocal microscopy demonstrates that Aβ
impairs the mitochondrial movement [117]. These ﬁndings indicate
that mitochondria are the targets of Aβ, and mitochondrial dysfunc-
tion happens at early stage of the disease, suggesting that early
mitochondria-targeted therapeutic interventions may be effective in
delaying AD progression in treating AD patients.
The mechanism of the inhibitory potential of the Aβ42 on activity
of electron transport chain enzyme complexes was investigated in
human mitochondria. Synthetic Aβ1–42 speciﬁcally inhibited the
terminal complex COX in a dose-dependent manner that was
dependent on the presence of Cu2+ and speciﬁc “aging” of the Aβ42
solution. Maximal COX inhibition occurred when using Aβ42
solutions aged for 3–6 h at 30 °C. The level of Aβ42-mediated COX
inhibition increasedwith aging time up to approximately 6 h and then
declined progressively with continued aging to 48 h [96]. Photo-
induced cross-linking of unmodiﬁed proteins followed by SDS-PAGE
analysis revealed dimeric Aβ as the only Aβ species to provide
signiﬁcant temporal correlation with the observed COX inhibition.
Analysis of brain and liver from an AD model mouse (Tg2576)
revealed abundant Aβ immunoreactivity within the brain mitochon-
dria fraction. These data indicate that endogenous Aβ is associated
with brain mitochondria and that Aβ1–42, possibly in its dimeric
conformation, is a potent inhibitor of COX, but only when in the
presence of Cu2+. Therefore, Cu2+-dependent Aβ-mediated inhibi-
tion of COX may be an important contributor to the neurodegenera-
tion process in AD [96]. Increased copper concentration has been
found in the AD brain that implies that copper may participate in the
pathophysiology of AD [118]. In fact, copper can bind to APP and Aβ,
then affects the structure and toxic of APP and Aβ, and then affect the
formation of beta-sheet structure that is widely accepted as toxic
secondary structure of Aβ [118].
To test the possibility that age-dependent decline in the
mitochondrial respiratory function, especially COX activity, may
participate in the formation and accumulation of Aβ, a neuron-
speciﬁc COX-deﬁcient mouse was ﬁrst generated by the Cre-loxP
system, in which the COX10 gene, which encodes the farnesyltrans-
ferase required for COX assembly and function, was deleted by a
CamKIIα promoter-driven Cre-recombinase. These knockout (KO)
mice showed an age-dependent COX deﬁciency in the cerebral cortex
and hippocampus. Then AD-like double transgenic mice expressing
mutants of APP and PS1 in a neuron-speciﬁc COX-deﬁcient back-
ground were generated. Surprisingly, COX10 KO mice exhibited
signiﬁcantly fewer amyloid plaques in their brains compared with the
COX-competent transgenic mice. This reduction in amyloid plaques in
the KO mouse was accompanied by a reduction in Aβ42 level, BACE1
activity, and oxidative damage. Likewise, production of ROS from cells
with partial COX activity was not elevated. Collectively, these results
suggest that, contrary to previous models, a defect in neuronal COX
does not increase oxidative damage nor predispose for the formationof amyloidogenic APP fragments [119,120]. On the other hand, this
study also indicates that genetic modiﬁcation of mitochondria can
inhibit ROS overproduction, eventually reduce Aβ level, prevents the
development and progress of AD, suggesting a useful approach for
treatment of the disease.
6. DNA damage in Alzheimer's disease
6.1. Deﬁnition of oxidative DNA damage
Increased ROS/free radical production/NO, either produced from
mitochondria or from inﬂammation process (macrophage/microglia
in brain) can cause oxidation of nucleotide acids, especially DNA. The
resulting DNA damages are present in most, if not all, human diseases,
including AD, and aging [15,121]. The toxic hydroxyl radical is known
to react with all components of the DNAmolecule, damaging both the
purine and pyrimidine bases and also the deoxyribose backbone
[15,85]. Therefore DNA is a particularly important target for oxidation,
as damage may lead to heritable alterations. Consequently, damage to
DNA has been well studied, and several classes of product identiﬁed:
base oxidation and fragmentation products (e.g. single- and double-
strand breaks); inter/intra-strand cross-links; DNA–protein cross-
links; and sugar fragmentation products [15,122]. The hydroxyl
radical is perhaps the most frequently form of ROS, with over twenty
different products formed from OH* attack on the bases in DNA. The
principal oxidative DNA damage products include 8-hydroxyadenine
(8-OH-Ade), 8-hydroxyguanine (8-OH-Gua; and its deoxynucleoside
equivalent, 8-OH-dG), 5,6-dihydroxy-5,6-dihydrothymine (thymine
glycol, Tg) and ring-opened lesions: 4,6-diamino-5-formamidopyr-
imidine (FapyAde) and 2,6-diamino-4-hydroxy-5-formamidopyrimi-
dine (FapyGua). Overall, the most extensively studied DNA lesion is
the formation of 8-OH-G and 8-OH-dG, which is widely accepted and
used as an oxidative DNA biomarker. Permanent modiﬁcation of
genetic material resulting from these oxidative damage incidents
represents the ﬁrst step involved in mutagenesis, aging and age-
related diseases, including cancer and neurodegenerative diseases
including AD.
6.2. Methods for detection of oxidative DNA damage
Oxidized DNA can be detected by several ways: 1) high pressure
liquid chromatography (HPLC) analysis for oxidized DNA from pure
genomic DNA; 2) immunohistochemistry analysis using brain sections
and antibody that is speciﬁc for 8-OHdG or 8-OHG; and 3) comet assay
that detects DNA damage in a single cell.
6.2.1. HPLC analysis using genomic DNA
DNA can be isolated from tissues or blood either by traditional
phenol extraction/ethanol precipitation (multiple) or a convenient
kit, the DNA purity and concentration are determined spectrophoto-
metrically. An OD of 1 at 260 nm corresponded to ~50 μg/ml DNA.
Only samples with a high degree of DNA purity (such as OD 260/230
ratio above 2.0), could be used for HPLC analysis. To avoid any
artiﬁcial DNA damage from phenol extraction, the salt methods have
been developed [123–125]. It has been shown that the sodium iodide
(NaI) isolation method is a more sensitive and reliable assessment of
8-oxo-2-deoxyguanosine levels than the classical phenol method
[126]. Relative commercial kits are also developed by companies such
as Qiagen, which may signiﬁcantly save the timing course.
Themeasurement of 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxo-
dG) (also called 8-hydroxy-2′-deoxyguanosine, 8-OHdG) is widely used
method for determining oxidative DNA in DNA sample [127,128]. In
brief, DNA will be digested and dephosphorylated by nuclease P1
followed by alkaline phosphatase. Digested DNA is analyzed by HPLC
equipped with a reverse-phase analytical column and coupled with a
photodiode array detector followed by an electrochemical (EC) detector.
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while themeasurement of 8-oxo-dGwasby EC detector (at 290 mV).On
the other hand, 8OHdG can also be determined in situ (brain or other
organs, different region and sub-region) locally using immunohisto-
chemistrywith a speciﬁc 8OHdG antibody, followingquantiﬁcationwith
Stereologer software, Image J or other software analysis.
6.2.2. Immunostaining analysis is a qualitative method to measure 8-
hydroxyguanosine (8-OHG), a marker for oxidative DNA damage in
brain sections of aging, AD mouse models and AD brains [93,129–131]
This method determines the accumulated oxidative DNA in cells.
There are several good quality antibodies are available to detect DNA
damage in the brain sections. Several studies quantiﬁed 8-OHG in the
brains of neurodegenerative diseases [132].
6.2.3. The comet assay is another useful genotoxicity test for DNA
damage [33,133,134]
In addition, puriﬁed DNA repair enzymes, applied to DNA during
the course of the comet assay procedure, greatly increase the
sensitivity and speciﬁcity of the assay. The kinetics of cellular repair
after low doses of oxidative damage have been followed with this
modiﬁed comet assay [135]. Therefore, the successful measurement of
biomarkers of oxidative damage in human populations establishes the
comet assay as a valuable tool in molecular epidemiology.
Overall these are useful methods to detect and quantify oxidized
DNA in cells. However, HPLC based method yields more accurate
oxidized DNA in cells.
6.3. Oxidative DNA damage in AD and therapeutic applications
In addition to Aβ stimulation of ROS production, which directly
causes DNA damage, it has been shown that Aβ42 has DNA nicking
activities similar to nucleases. Further, magnesium ion was shown to
enhance the DNA nicking activity of Aβ, and Aβ oligomers showed
more DNA nicking activity compared to monomers and ﬁbrillar forms.
These data support a role for Aβ in causing direct DNA damage
[33,136].
In the Tg2576 mouse model of AD, at the age of three months the
mice show no apparent signs of behavioral, neuroanatomical,
cytological, or biochemical alterations. However, recent biochemical
and morphological studies demonstrated that signiﬁcant alterations
in several antioxidant proteins are already detectable at this early
stage of the disease and protein composition change concomitantly
with early oxidative stress. Interestingly, the neocortex shows a
compensatory response, consisting in an increase of ROS scavenging
enzymes, while the hippocampus appears more prone to the
oxidative insult [137].
The accumulation of DNA damage can be particularly deleterious
in postmitotic cells such as neurons, which are not self-renewed
through cell proliferation. Therefore, the accumulation of oxidative
DNA damage in nuclear DNA (nDNA) is believed to result in a slow
build-up of DNA adducts in the genome able to trigger neuronal death,
whereas its accumulation in the mitochondrial DNA (mtDNA) can
result in base substitutions and deletions leading to the erroneous
transcription of genes encoding important subunits of the electron
transport chain, with subsequent mitochondrial dysfunction, in-
creased oxidative damage, and neuronal death [33]. It has been
shown that mtDNA is particularly sensitive to oxidative damage. In
postmortem brain tissue there was a signiﬁcant threefold increase in
the amount of 8OHdG in mtDNA in parietal cortex of AD patients
compared with controls. In the entire group of samples there was a
small but signiﬁcant increase in oxidative damage to nDNA and a
highly signiﬁcant threefold increase in oxidative damage to mtDNA in
AD compared with age-matched controls [138]. Comparing levels of
lipid peroxidation in any of the brain regions no differences were
found, and a signiﬁcant difference was found only in the parietal lobe,increased levels of 8-hydroxyadenine, 8-hydroxyguanine, thymine
glycol, Fapy-guanine, 5-hydroxyuracil, and Fapy-adenine, oxidized
DNA bases were observed in parietal, temporal, occipital, and frontal
lobe, superior temporal gyrus, and hippocampus. The baseline level of
oxidative DNA damage in the temporal lobe was higher than in other
brain regions in both control and AD brain [139]. Similarly, levels of
multiple oxidized bases in AD brain specimens were signiﬁcantly
higher in frontal, parietal, and temporal lobes compared to control
subjects, whereas cerebellum was only slightly affected in AD brains;
mtDNA had approximately 10-fold higher levels of oxidized bases
than nDNA. Oxidative DNA damage was also found in mild cognitive
impairment (MCI), the phase between normal aging and early
dementia [140–142]. These data are consistent with higher levels of
oxidative stress in mitochondria, suggesting that oxidative damage to
mitochondrial DNA may contribute to the neurodegeneration of AD,
including the earliest detectable phase of AD. Interestingly, the fact
that mtDNA hasmore oxidative damage also conﬁrmed by the reliable
assessment using the NaI isolation method, which showed that the
levels of 8oxodG in mtDNA isolated frommouse liver, heart and brain
were 6-, 16- and 23-fold higher than nDNA from these tissues. The
steady-state levels of oxo8dG in mouse tissues range from 180 to 360
lesions in the nuclear genome and from one to two lesions in 100
mitochondrial genomes [19].
Interestingly, point mutation frequencies in mtDNA were 2 to
3-fold higher in the parietal gyrus, hippocampus, and cerebellum from
AD subjects compared to normal controls. In contrast, levels of a
commonly studied deletion mutation, mtDNA (4977), were not
elevated in AD. The frequency of point mutations did not vary
signiﬁcantly among the three brain areas, whereas the frequency of
mtDNA (4977) was 15- to 25-fold lower in the cerebellum in
comparison to the cortex; this regional variation was seen in both
the normal and AD brain [143]. It has also been shown that somatic
mtDNA control region (CR) mutations accumulate with age in post-
mitotic tissues including the brain and that the level of mtDNA
mutations is markedly elevated in the brains of AD patients [144]. The
elevated mtDNA CR mutations in AD brains are associated with a
reduction in the mtDNA copy number and in the mtDNA L-strand
transcript levels. Further, mtDNA CR mutations increase with age in
control brains; that they are markedly elevated in the brains of AD,
Down syndrome (DS) and dementia (DSAD) patients. The increased
mtDNA CR mutation rate is also seen in peripheral blood DNA and in
lymphoblastoid cell DNAs of AD and DSAD patients, and distinctive
somaticmtDNAmutations, often at high heteroplasmy levels, are seen
in AD and DSAD brain and blood cells DNA. In aging, DS, and DSAD, the
mtDNAmutation level is positively correlatedwith BACE1 activity and
mtDNA copy number is inversely correlated with insoluble Aβ40 and
Aβ42 levels [145]. These data further indicate that increased Aβ,
which produced by BACE1, causes the signiﬁcant elevation of mtDNA
mutation, and this mtDNA mutation may be responsible for both age-
related dementia and the associated neuropathological changes
observed in AD and DSAD.
Overall oxidative DNA damage, especially mitochondria DNA
damage in AD brain is a basic event during the initiation and
development of the disease. Interestingly, increasing data including
ours have shown that antioxidants such as CoQ and its variants, and
that antioxidant enzymes and transcription factors such as NrF2, can
signiﬁcantly reduce ROS production and tissue damage, eventually
improve cell survival and cellular function in vitro and in vivo [146–
149] (Fig. 2). Some of traditional Chinese medicines/herbal medicines
may also works as antioxidants, neuroprotectants and/or mitochon-
drial boosters, such as Ginkgo biloba and Ginseng, therefore more
studies in humans with strong methodology may provide useful
information or effective medicine in the ﬁeld [148,150].
Recently we crossed APP transgenic mouse with mitochondria-
targeted catalase mouse (MCAT) and produced MCAT/APP double
transgenic mice. We found that MCAT not only signiﬁcantly reduces
Fig. 2. Protective therapeutic approaches that decrease oxidative DNA damage in aging
and AD. 1. Mitochondria-targeted antioxidants, 2. overexpression of mitochondria-
localized sirtuins 3–5, 3. mitochondria DNA repair enzymes, 4. increased levels of
insulin-like growth factor 1 and 5. overexpression of nuclear transcription factors.
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eventually elongates the AD mouse lifespan (Mao and Reddy,
unpublished results). These observations suggest that mitochondria-
targeted antioxidants may be a potential therapeutic approach for AD.
Notably, a placebo-controlled, double-blind, randomized trial
showed that a safe and effective medicine, huperzine A (400 μg/day
for 12 weeks), which was originally isolated from the Chinese herb
Lycopodium serratum, also known in China as Qian Ceng Ta or Jin Bu
Huan, remarkably improves the cognition, behavior, activity of daily
life, and mood of AD patients [151], conﬁrmed early report, which
concluded that huperzine A is a promising drug for symptomatic
treatment of AD [152]. In a phase II trial of huperzine A in mild to
moderate AD in the US, huperzine A 200 μg BID did not inﬂuence
change in ADAS-Cog at 16 weeks. In secondary analyses, huperzine A
400 μg BID showed a 2.27-point improvement in ADAS-Cog at
11 weeks vs 0.29-point decline in the placebo group (p=0.001),
and a 1.92-point improvement vs 0.34-point improvement in the
placebo arm (p=0.07) at week 16 [153]. Therefore, overall Huperzine
A is a well-tolerated drug that could signiﬁcantly improve cognitive
performance in patients with AD, and it appears to be more effective
than FDA approved acetylcholinesterase inhibitors, AChEIs [150,154–
156]. Considering the study design was not strong, sample sizes were
still small, as well as individuals vary for an optimal effective dose,
rigorous design, randomized, multi-center, large-sample trials of
huperzine A and its derivatives for AD are needed to further assess the
effects.
7. DNA repair as a therapeutic strategy in Alzheimer's disease
Despite that oxidative DNA damage plays an important role in
aging and diseases, including AD, as there are multiple pathways for
its repair, clearly the cell does not want this damage to persist.
Terminally differentiated neurons in the adult brain are able to re-
enter the cell-division cycle under certain circumstances [157]. In
humans, circumstantial evidence comes from diseases with DNA
repair defects, such as Xeroderma Pigmentosum, which shows an
accumulation of oxidative DNA damage and increased frequency of
skin cancers and, in certain cases, characteristic neurological degen-
eration. There are several reviews summarized the recent progress on
DNA repair, especially in neurodegenerative diseases, in both nDNA
and mtDNA [33,158–161].
Among many repair pathways, the base excision repair (BER)
pathway is the most important cellular protection mechanism
responding to oxidative DNA damage. The BER pathway has beenextensively studied in AD brains, and it is of particular importance in
post mitotic tissues such as brain tissues, where simple base
modiﬁcations are more likely to occur than major DNA damage.
The key enzymes in the BER process are DNA glycosylases, which
remove different damaged bases by cleavage of the N-glycosylic
bonds between the bases and the deoxyribose moieties of the
nucleotide residues. To complete the repair after glycosylase action,
the apurinic/apyrimidinic (AP) site is further processed by an incision
step, DNA synthesis, an excision step, and DNA ligation through two
alternative pathways. The short-patch BER (1-nucleotide patch size)
and long-patch BER (2-6-nucleotide patch size) pathways need AP
endonuclease to generate a 3′ hydroxyl group but require different
sets of enzymes for DNA synthesis and ligation. Protein–protein
interactions have been reported among the enzymes involved in BER.
It is proposed that the successive players in the repair pathway are
assembled in a complex to perform concerted actions [33,158]. It has
been shown that the activity of most enzymes/proteins involved in
DNA repair were down-regulated in AD brains [33,162], indicating a
deﬁciency of the DNA repair system in such degenerative diseases.
For many years, the repair of most damage in mtDNA was thought
limited to short-patch base excision repair (SP-BER), which replaces a
single nucleotide by the sequential action of DNA glycosylases, an AP
endonuclease, the mtDNA polymerase gamma, an abasic lyase
activity, and mtDNA ligase. However, recent studies have consider-
ably expanded our knowledge of mtDNA repair to include many
mechanisms seen in nDNA repair, such as long-patch base excision
repair (LP-BER), mismatch repair, and homologous recombination
and nonhomologous end-joining [161,163]. In addition, elimination of
mutagenic 8-oxodeoxyguanosine triphosphate helps prevent cell
death due to the accumulation of this oxidation product in mtDNA.
Also, recent evidence provided that irreparably damaged mtDNA
might be targeted for degradation. Therefore, multiple DNA repair
pathways and controlled degradation of mtDNA function together to
maintain the integrity of mitochondrial genome [163].
The mammalian mitochondrial protein TFAM was originally iden-
tiﬁed as a transcription factor (A) but also appears to play a direct role in
DNA repair. TFAM binds stronger to oxidatively damaged DNA than to
intact DNA and shows higher afﬁnity for 8-oxoG-containing base pairs
than the relevant OGG1 and MYH DNA glycosylases [164,165]. Recent
data suggest that TFAM indeed modulates the BER pathway in
mitochondria by virtue of its DNA-binding activity and protein
interactions [166]. TFAM also binds to p53, a tumor suppressor which
localizes to mitochondria in response to death signals [167]. On the
other hand, the 3′–5′ exonuclease activity of p53 canhydrolyze oxidized
nucleotides like 8-oxodG at DNA 3′-ends, a reaction which is enhanced
upon interaction with the mitochondrial single-stranded DNA-binding
protein (mtSSB) [168].
In mammalian cells, oxidative damage to the mitochondrial DNA
also correlates with the translocation of the tumor suppressor p53 to
the organelles, which introduces a further regulation level, as p53 is
thought to modulate DNA repair. Furthermore, p53 stimulates both
removal of damaged bases and nucleotide re-insertion [169].
Although aging is clearly associated with modiﬁcations in
mitochondrial DNA repair capacity, the situation is contrasted. This
may also reﬂect a balance between DNA damage and repair, as
mitochondrial DNA oxidative damage is inversely correlated with
maximum life span in mammals [169] (Fig. 3). On the other hand,
changes in mitochondrial BER play a role in DNA damage accumu-
lation and age-related functional decline [34]. In mammals, variations
in organelle BER capacity with age appear to be organ and tissue-
speciﬁc [170], for example, increased BER enzyme activities in
mitochondria can be found in liver [158] or gradual decline in brain
[171–173].
Base excision repair is thought to be the primary DNA repair
pathway for small base modiﬁcations such as oxidation. Bohr's group
employed a set of functional assays to measure BER activities in brain
Fig. 3. DNA repair mechanisms of mitochondrial and nuclear genomes.
1367P. Mao, P.H. Reddy / Biochimica et Biophysica Acta 1812 (2011) 1359–1370tissue from short post-mortem interval autopsies of sporadic AD
patients and age-matched controls, as well as amnestic mild cognitive
impairment (MCI) subjects. They found signiﬁcant BER deﬁciencies in
brains of AD patients due to limited DNA base damage processing by
DNA glycosylases and reduced DNA synthesis capacity by DNA
polymerase β. Interestingly the BER impairment was not restricted
to damaged brain regions and was also detected in the brains of
amnestic MCI patients, where it correlated with the abundance of
neuroﬁbrillary tangles. These ﬁndings suggest that BER dysfunction is
a general feature of AD brains that could occur at the earliest stages of
the disease. The results support that defective BER may play an
important role in the progression of AD, and that mitochondrial BER
might be critical in the development and maintenance of the central
nervous system during aging [174].
As summarized in Fig. 3, overall, these studies indicate that DNA
repair in both mitochondrial and nuclear genomes are involved in AD,
and recent research advancements may help develop strategies to
repair DNA changes that are caused by aging, Aβ, hyperphosphory-
lated and other oxidative insults.
8. Conclusions and future directions
Increasing evidence suggests that mitochondrial oxidative damage
is an early event and plays a key role in the progression and
pathogenesis of AD. Recent AD postmortem brains, transgenic mouse
models and cell models of AD revealed that Aβ signiﬁcantly induces
DNA damage in age-dependent manner in neurons from patients with
AD or AD-like animal models. Aβ also induces oxidative mtDNA
damage, in turn, generates excessive free radicals, and causes more
DNA damage, it likely forms a vicious cycle. On the other hand,
antioxidant system, DNA repair and neurogenesis (including adult
stem cells in brain) are functionally going down in aged humans and
AD patients. All these factors and pathways likely work together to
induce synapse and neuron damage, eventually neuron loss in AD
patients.
Given the complexities of AD, therapies that target the causes and
different mechanisms simultaneously would be effective. A strategy
using a multifaceted therapy that targets Aβ, hyperphosphorylated
tau, and mitochondrial oxidative damage may be an ideal approach.
More importantly, evidence from clinical trials and studies of
experimental therapeutics of AD mouse models indicate that early
treatment is the key for cure or effective treatment of the disease.
Similarly, prevention of the AD from happening in our populations is
another best way to ﬁght this number one of the common progressive
neurodegenerative diseases.
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